Emmaus Q3 Revenue Falls to $1.9M, Net Loss Widens to $4.7M
EMMA has more than doubled off its 52-week low of $0.008 on light trading volume (0.1× avg).
Summary
Emmaus reported Q3 2026 net revenue of $1.9 million versus $3.4 million a year ago and a net loss of $4.7 million, with cash down to $1.0 million against $72.9 million of current liabilities.
Key Events · Earnings and Guidance · EMMA
-
Q3 Revenue Falls 44% in U.S.
Net revenues were $1.9 million for the three months ended September 30, 2026 versus $3.4 million a year earlier, driven by a 44% decrease in U.S. net revenues after the NeoImmuneTech license became effective May 15, 2026.
-
Net Loss Widens to $4.7M
Net loss was $4.7 million, or $0.07 per basic share on roughly 70.2 million weighted-average shares, versus $2.1 million, or $0.03 per share, a year ago.
-
Derivative Mark-to-Market Drives Other Expense
Other expense rose to $4.4 million from $2.2 million, primarily a non-cash change in fair value of the conversion feature derivative tied to an increase in the stock price—no cash outflow and no new shares.
-
Cash Down to $1.0M
Cash and cash equivalents were $971 thousand at September 30, 2026 versus $2.1 million at December 31, 2025, against total current liabilities of $72.9 million and a stockholders' deficit of $68.7 million.
Analysis · EMMA · Life Sciences
The NeoImmuneTech licensing deal, effective May 15, 2026, took over Endari sales and drove a 44% drop in U.S. revenue, flipping the company from a $0.7 million operating profit a year ago to a $0.4 million operating loss. The larger swing sits below the operating line: other expense jumped to $4.4 million, mostly a non-cash mark-to-market change on the conversion feature derivative tied to a higher share price—neither a cash outflow nor new dilution. With cash down to $1.0 million from $2.1 million at year-end against $72.9 million of current liabilities, the going-concern doubt previously disclosed in the Q2 10-Q remains the central issue.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EMMA was trading at $0.02 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.6M. The 52-week trading range was $0.01 to $0.09. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.